에다라본 약제학적 조성물

본 발명에는 에다라본 악제학적 조성물 및 설하 제제로서의 이의 적용, 에다라본 또는 이의 염 및 만니톨을 함유하는 약제학적 조성물이 개시되어 있다. 설하 투여 제제는 간의 제1 통과 효과를 피할 수 있고, 샘플은 다른 이점 중에서 우수한 안정성, 수송의 편의성 및 용도를 특징으로 한다. Disclosed in the present invention are an edaravone pharmaceutical composition and an application thereof as a sublingual preparation, the...

Full description

Saved in:
Bibliographic Details
Main Authors ZHAO XINGQUAN, WANG YONGJUN, WANG YILONG, ZHANG ANYUAN
Format Patent
LanguageKorean
Published 23.12.2020
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract 본 발명에는 에다라본 악제학적 조성물 및 설하 제제로서의 이의 적용, 에다라본 또는 이의 염 및 만니톨을 함유하는 약제학적 조성물이 개시되어 있다. 설하 투여 제제는 간의 제1 통과 효과를 피할 수 있고, 샘플은 다른 이점 중에서 우수한 안정성, 수송의 편의성 및 용도를 특징으로 한다. Disclosed in the present invention are an edaravone pharmaceutical composition and an application thereof as a sublingual preparation, the pharmaceutical composition containing edaravone or a salt thereof and mannitol. A sublingual administration preparation can avoid the first-pass effect of the liver, and samples feature good stability, convenience of transport and of use, among other advantages.
AbstractList 본 발명에는 에다라본 악제학적 조성물 및 설하 제제로서의 이의 적용, 에다라본 또는 이의 염 및 만니톨을 함유하는 약제학적 조성물이 개시되어 있다. 설하 투여 제제는 간의 제1 통과 효과를 피할 수 있고, 샘플은 다른 이점 중에서 우수한 안정성, 수송의 편의성 및 용도를 특징으로 한다. Disclosed in the present invention are an edaravone pharmaceutical composition and an application thereof as a sublingual preparation, the pharmaceutical composition containing edaravone or a salt thereof and mannitol. A sublingual administration preparation can avoid the first-pass effect of the liver, and samples feature good stability, convenience of transport and of use, among other advantages.
Author WANG YONGJUN
WANG YILONG
ZHAO XINGQUAN
ZHANG ANYUAN
Author_xml – fullname: ZHAO XINGQUAN
– fullname: WANG YONGJUN
– fullname: WANG YILONG
– fullname: ZHANG ANYUAN
BookMark eNrjYmDJy89L5WRQfjN9wuvuJa_n7nm9eYfCm6l73yyY83bqzDcLGhXeLNzwpmXj6zV7eBhY0xJzilN5oTQ3g7Kba4izh25qQX58anFBYnJqXmpJvHeQkYGRgYGhibGJuamjMXGqABLwM-I
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID KR20200143475A
GroupedDBID EVB
ID FETCH-epo_espacenet_KR20200143475A3
IEDL.DBID EVB
IngestDate Fri Jul 19 12:47:32 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Korean
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_KR20200143475A3
Notes Application Number: KR20207032975
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20201223&DB=EPODOC&CC=KR&NR=20200143475A
ParticipantIDs epo_espacenet_KR20200143475A
PublicationCentury 2000
PublicationDate 20201223
PublicationDateYYYYMMDD 2020-12-23
PublicationDate_xml – month: 12
  year: 2020
  text: 20201223
  day: 23
PublicationDecade 2020
PublicationYear 2020
RelatedCompanies BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL UNIVERSITY
NANJING BAIXINYU PHARMACEUTICAL CO., LTD
RelatedCompanies_xml – name: BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL UNIVERSITY
– name: NANJING BAIXINYU PHARMACEUTICAL CO., LTD
Score 3.262485
Snippet 본 발명에는 에다라본 악제학적 조성물 및 설하 제제로서의 이의 적용, 에다라본 또는 이의 염 및 만니톨을 함유하는 약제학적 조성물이 개시되어 있다. 설하 투여 제제는 간의 제1 통과 효과를 피할 수 있고, 샘플은 다른 이점 중에서 우수한 안정성, 수송의 편의성 및 용도를 특징으로...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title 에다라본 약제학적 조성물
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20201223&DB=EPODOC&locale=&CC=KR&NR=20200143475A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMQYd-GFglqxrmWKWqmsC7CjrWqQA03KKGbAuTE5LAtUaoNUWfmYeoSZeEaYRTAw5sL0w4HNCy8GHIwJzVDIwv5eAy-sCxCCWC3htZbF-UiZQKN_eLcTWRQ3aOzYCTRQZq7k42boG-Lv4O6s5O9t6B6n5BYHlQEfZmZibOjIzsAIb0uagBWCuYU6gfSkFyJWKmyADWwDQvLwSIQam7HxhBk5n2N1rwgwcvtApbyATmvuKRRiU30yf8Lp7yeu5e15v3qHwZureNwvmvJ06882CRoU3Cze8adn4es0eUQZlN9cQZw9doG3xcM_FewchO81YjIEF2O1PlWBQSAOGm4VBinFSSiroWLxUSxOLtBQzA2OLFFNLk1TTJEkGGXwmSeGXlmbgAnFBCzOMjGUYWEqKSlNlgdVrSZIcOFQAyr-G6w
link.rule.ids 230,309,783,888,25578,76884
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMQYd-GFglqxrmWKWqmsC7CjrWqQA03KKGbAuTE5LAtUaoNUWfmYeoSZeEaYRTAw5sL0w4HNCy8GHIwJzVDIwv5eAy-sCxCCWC3htZbF-UiZQKN_eLcTWRQ3aOzYCTRQZq7k42boG-Lv4O6s5O9t6B6n5BYHlQEfZmZibOjIzsAIb2Ragk_Zdw5xA-1IKkCsVN0EGtgCgeXklQgxM2fnCDJzOsLvXhBk4fKFT3kAmNPcVizAov5k-4XX3ktdz97zevEPhzdS9bxbMeTt15psFjQpvFm5407Lx9Zo9ogzKbq4hzh66QNvi4Z6L9w5CdpqxGAMLsNufKsGgkAYMNwuDFOOklFTQsXipliYWaSlmBsYWKaaWJqmmSZIMMvhMksIvLc_A6RHi6xPv4-nnLc3ABZICLdIwMpZhYCkpKk2VBVa1JUly4BACAEY2ids
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=%EC%97%90%EB%8B%A4%EB%9D%BC%EB%B3%B8+%EC%95%BD%EC%A0%9C%ED%95%99%EC%A0%81+%EC%A1%B0%EC%84%B1%EB%AC%BC&rft.inventor=ZHAO+XINGQUAN&rft.inventor=WANG+YONGJUN&rft.inventor=WANG+YILONG&rft.inventor=ZHANG+ANYUAN&rft.date=2020-12-23&rft.externalDBID=A&rft.externalDocID=KR20200143475A